Novel Molecular Imaging Technology Could Improve Tumor Margin Assessment During Breast Cancer Surgery
Executive Summary
A novel molecular imaging technology for intraoperative assessment of tumor margins during breast cancer surgery is positioned to not only improve patient outcomes, but to also reduce costs by eliminating the need for repeat surgeries. Lightpoint Medical has already received the CE mark for its product, which could be developed for use in other cancers, and a US launch could come as early as the first quarter of 2016.
You may also be interested in...
Innovation In The Age Of Breast-Conserving Surgery
Medical device and diagnostic companies are developing innovative new products for women with breast cancer designed to facilitate earlier diagnosis, improve diagnostic accuracy, increase surgical precision, and enable the least invasive, most breast-conserving approach to breast cancer surgery. With the number of breast cancer cases in the US projected to increase dramatically by 2030, the success of these technologies depends on their ability to improve cosmetic results and survival rates while lowering overall health care costs.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.